Korea Moves to Garner More Roche Tamiflu, GSK Relenza Against Swine Flu
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The South Korean government is moving quickly to garner more of Roche's Tamiflu (oseltamivir) and Biota's Relenza (zanamivir) in its prevention against the swine flu virus reported in Mexico, the U.S. and the UK
You may also be interested in...
Korea Expands National Medical Insurance Coverage Of Tamiflu, Relenza To Fight Swine Flu
SEOUL - With global health authorities warning of the possibility of the swine flu blooming into a pandemic, Korea's Ministry for Health, Welfare and Family Affairs has begun to cover Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) under the National Medical Insurance System for those likely exposed to the swine flu
Korea Expands National Medical Insurance Coverage Of Tamiflu, Relenza To Fight Swine Flu
SEOUL - With global health authorities warning of the possibility of the swine flu blooming into a pandemic, Korea's Ministry for Health, Welfare and Family Affairs has begun to cover Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) under the National Medical Insurance System for those likely exposed to the swine flu
Health Officials Across Asia Raise Alert Levels For Swine Flu
HONG KONG - A new strain of swine flu that surfaced in Mexico and has spread to parts of North America prompted authorities in Asia to heighten alert levels and to renew their calls for a new vaccine, and has caused stock prices to drop across Asia